Heart drug tafamidis shows promise in korean ATTR-CM patients
NCT ID NCT06321523
First seen Nov 20, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study looked at how well the drug tafamidis works for Korean patients with a rare heart condition called ATTR-CM. Researchers tracked 13 patients who were already taking the drug to see if it improved their heart function, symptoms, and quality of life. The goal was to understand the real-world benefits and safety of tafamidis in this specific group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gangnam Severance Hospital
Seoul, 06273, South Korea
-
Pusan National University Hospital
Busan, 49241, South Korea
-
Samsung Medical Center
Seoul, Seoul-teukbyeolsi [seoul], 06351, South Korea
-
Severance Hopital, Yonsei University Health System
Seoul, Seoul-teukbyeolsi [seoul], 03722, South Korea
Conditions
Explore the condition pages connected to this study.